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Abstract
 
B7-DC is a recently discovered member of the B7 family that binds to PD-1 and is selectively
expressed by dendritic cells (DCs). It has been shown to either costimulate or inhibit T cell re-
sponses. To assess the role of B7-DC in DC–T cell interactions, DCs from B7-DC knockout
(KO) mice were generated and compared with DCs from wild-type (WT) and B7–1/B7–2
double KO mice. B7–1/B7–2–deficient DCs, while strongly diminished in their ability to
stimulate naive CD4
 
 
 
 T cells, nonetheless retain partial activity. DCs from B7-DC KO mice
are diminished in their ability to activate CD4
 
 
 
 T cells, demonstrating that DC-expressed
B7-DC serves a predominantly stimulatory rather than inhibitory function in the initiation of
T cell responses. B7-DC costimulates expression of CD40L with faster kinetics than B7–1 and
displays potent synergy with B7–1 and B7–2 for T cell proliferation and cytokine production,
indicating that these B7 family members work in concert to stimulate T cells. Finally, costimu-
lation with B7-DC alone or in conjunction with B7–1 is PD-1 independent, indicating that
B7-DC costimulates T cells via a second receptor.
Key words: B7 • CD40L • costimulatory molecule • PD-1 • T cell activation
 
Introduction
 
DCs play a pivotal role at the intersection of innate and
adaptive immune responses (1, 2). The unique character of
DCs as APCs for T cells derives from multiple mechanisms
including high levels of peptide–MHC complexes to en-
gage the TCR (signal 1), high levels of adhesion molecules,
chemokine production, and a large variety of costimulatory
signals (so called signal 2). The B7 family of costimulatory
molecules is particularly important in regulating T cell re-
sponses (3–5). The originally described members of the
B7 family, B7–1 and B7–2, both costimulate through
CD28. However, T cell activity is down-modulated by a
second receptor for B7–1 and B7–2, CTLA-4. While B7–1
and B7–2 were once thought to represent the major
source of signal 2 by DCs, the recent discovery of addi-
tional B7 family members highlights the molecular com-
plexity of costimulation.
To elucidate the unique biology of DCs, we have
screened subtractive cDNA libraries between DCs and acti-
vated macrophages in order to identify genes selectively ex-
pressed by DCs. This screen identified a B7 family member,
termed B7-DC (also termed PD-L2), which costimulates
naive T cells to proliferate and produce cytokines such as
 
IL-2 and IFN-
 
 
 
 (6). Murine B7-DC/PD-L2 is highly simi-
lar (34% identity) to another B7 family member, B7-H1/
PD-L1, and both bind PD-1 (7, 8). Despite their homology
and similar ligand binding, B7-DC and B7-H1 have very
distinct expression patterns, while B7-H1 is expressed on all
hematopoetic cells and many nonhematopoietic tissues and
tumors, B7-DC surface expression is generally restricted to
DCs and a limited subset of macrophages (6, 9–11).
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B7-DC Costimulates CD4
 
 
 
 T Cells Independent of PD-1
 
More than simply a redundant costimulator, B7-DC is a
functionally complex and enigmatic molecule. We recently
found that B7-DC cross-linking with an IgM antibody ac-
tivated DCs, suggesting that B7-DC can serve as a bidirec-
tional amplification signal between DCs and T cells (12). In
contrast, Latchman et al. reported this molecule to be in-
hibitory to stimulation of T cells (particularly preactivated
T cells) in keeping with the apparent inhibitory role of its
receptor, PD-1 (10). Addition of anti–B7-DC antibodies to
DC–T cell cultures enhanced T cell stimulation. This result
was interpreted as inhibition of a negative signal delivered
to T cells by B7-DC (13).
The apparently discrepant activities of B7-DC have been
explained by evoking the ITSM motif in the intracytoplas-
mic domain of PD-1, which could switch the signal be-
tween a costimulatory and an inhibitory pathway (14). Al-
ternatively, a second activating receptor may be operative.
Another critical question is the interaction between B7-
DC and the B7–1/B7–2 system, as all these molecules are
coexpressed on DCs. To directly assess the function of B7-
DC alone and together with the B7–1/B7–2 system, we
have analyzed T cell activation using a combination of DCs
deficient in expression of these B7 family genes as well as Ig
fusion molecules and transfectants. These experiments con-
firm the costimulatory function of B7-DC and further
demonstrate a potent synergy with B7–1/2, particularly at
low levels of TCR stimulation. The costimulatory activity
of B7-DC is mediated by a receptor other than PD-1.
 
Materials and Methods
 
Mice.
 
B7-DC KO mice were produced as previously de-
scribed (12,15). BALB/c, C57BL/6, and B7–1/B7–2 knockout
mice were purchased from The Jackson Laboratory. B6-OT-II
TCR transgenic mice and BALB/c-6.5 mice and B6-PD-1
knockout mice were gifts from R. Schwartz (National Institutes
of Health, Bethesda, MD), H. Von Boehmer (Dana Farber Can-
cer Institute, Boston, MA), and T. Honjo (Kyoto University, Ky-
oto, Japan), respectively.
 
Antibodies and Reagents.
 
PE-conjugated anti–mouse B7-DC
(TY25) and anti–mouse B7-H1 (MIH6) monoclonal antibodies
were purchased from eBioscience. CD3 (2C11) and CD16/32
(2.4G2) mAb, FITC-CD4 (RM4–5), CD11c (HL3) mAbs, PE-
CD80 (1G10), CD86 (GL1), CD40L (MR-1), H-2
 
d
 
 (28–14–8),
I-A
 
b
 
 (25–9-17), and I-E
 
k/d
 
 (14–4-4s) mAbs were purchased from
BD Biosciences.
 
Cell Preparations and Cultures.
 
For T cell assays, CD4
 
 
 
 T cells
were purified by using a CD4
 
 
 
 T cell negative selection
kit (MACS; Miltenyi Biotec). Bone marrow–derived DCs
(BMDCs)
 
*
 
 were prepared following the previously described
methods (16) with GM-CSF (1,000 U/ml) and IL-4 (1,000 U/ml).
A.E7 is a CD4
 
 
 
 Th1 clone specific for the pigeon cytochrome c
peptide 81–104 and was grown and maintained as described pre-
viously (17).
 
Transfections.
 
Murine B7-DC and B7–1 cDNA cloned into
pCAGGS vector were transfected into RENCA cells (R-DC and
R-B7–1, respectively) using GeneJammer (Stratagene). Stable
 
transfectants were selected with blasticidine and cloned using lim-
iting dilution culture conditions.
 
Ag Presentation Assay by RENCA Transfectants.
 
RENCA cell
lines expressing B7-DC, B7–1, or both were used as APC to
present HA
 
110–120
 
 peptide to specific 6.5 TCR transgenic CD4
 
 
 
T cells. Prior to the presentation assay, RENCA transfectants
were treated 3 d with 100 ng/ml of IFN-
 
 
 
 (R&D Systems) to in-
duce surface expression of I-E
 
d
 
 molecules. Cells were irradiated
(13,200 rad), washed, and plated at 10
 
5
 
 cells/well in 96 flat-bot-
tom plates in presence of 1 to 10 
 
 
 
g/ml HA peptide and 10
 
5
 
CD4
 
 
 
 6.5 TCR transgenic splenocytes. Proliferation was deter-
mined by labeling cultures for the last 10–18h of a 3-d assay with
1 
 
 
 
Ci [
 
3
 
H]thymidine/well.
 
T Cell Costimulation Assays.
 
High-bound 96-well plates
(Immulon4; Dynex) were coated 90 min at 37
 
 
 
C with 3 ng/well
or 30 ng/well of anti-CD3 (2C11; BD Biosciences) in presence
or absence of B7–1-Ig or B7–2-Ig (R&D Systems), and/or B7-
DC-Ig dimer, which consists of a full mouse IgG1 in which the
variable domains of the heavy chain have been substituted with
the extracellular domain of mouse B7-DC.
 
Results
 
Stimulatory Properties of BM-derived DCs from B7-DC KO
and B7–1/B7–2 KO Mice.
 
To definitively determine
whether B7-DC expression by DCs enhances or inhibits
their ability to stimulate T cells, B7-DC KO mice were
generated as a source of DCs. The mice did not display any
overt evidence of autoimmunity, immune deficiency, or
other pathology up to one year of age. Cell numbers and
gross phenotype of the thymus, spleen, and lymph nodes
were normal in B7-DC KO animals. For analysis of DC
function, BMDCs generated from B7-DC KO mice were
assessed for their stimulatory properties. We assessed the
stimulatory properties of BMDCs from B7–1/B7–2 KO
mice as well in order to determine whether DCs could
stimulate CD4
 
 
 
 T cells in the absence of these primary co-
stimulatory molecules. BMDCs were cultured for 6 d with
GM-CSF and an additional 2 d with GM-CSF and IL-4. In
a reciprocal fashion, mechanically activated BMDCs from
B7–1/B7–2 KO mice failed to express B7–1 and B7–2 but
expressed high levels of B7-DC and I-A
 
b
 
.
CD4
 
 
 
 T cells from young OT-II transgenic mice were
cocultured with DCs from either wt, B7–1/B7–2 KO, or
B7-DC KO mice in the presence of varying peptide con-
centrations and T cell proliferation, IL-2 and IFN-
 
 
 
 pro-
duction were measured. Fig. 1 shows that unstimulated
OT-II T cells responded to OVA
 
323–339
 
 peptide presented
by B7–1/B7–2
 
 
 
/
 
 
 
 DCs although to a much lesser extent
than wt DCs. These results suggested that B7–1/B7–2
 
 
 
/
 
 
 
DCs express additional molecules capable of providing co-
stimulation to T cells. Stimulation of OT-II cells by B7-
DC
 
 
 
/
 
 
 
 DCs was diminished relative to wt DCs although it
was greater than with B7–1/B7–2
 
 
 
/
 
 
 
 DCs. In parallel with
the proliferation results, IFN-
 
 
 
 production by OT-II cells
was diminished with B7-DC
 
 
 
/
 
 
 
 DCs, though not as much
as with B7–1/B7–2
 
 
 
/
 
 
 
 DCs. These results demonstrate
that B7-DC provides a positive rather than inhibitory sig-
nal for initiating CD4
 
 
 
 T cell activation.
 
*
 
Abbreviation used in this paper:
 
 BMDC, bone marrow–derived DC.T
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Differential Kinetics and Synergy between B7-DC and B7–1–
mediated Costimulation of CD4
 
 
 
 T Cells.
 
To further assess
the costimulatory capacity of B7-DC, alone and in con-
junction with B7–1, a series of in vitro experiments using
immobilized B7–1 and/or B7-DC (as Ig dimers) and
RENCA cells expressing B7–1 and/or B7-DC, were per-
formed. Initially, stimulation of CD4
 
 
 
 T cells was assessed
by analyzing the expression of T cell activation markers
such as CD40L, CD25 and CD69. Fig. 2 demonstrates that
for both high and low concentrations of anti-CD3 (signal
1), B7-DC-Ig costimulates the expression of CD40L with
much faster kinetics than B7–1, inducing significant up-
regulation after 6 h. In contrast B7–1 costimulation of
CD40L was not observed until 18 h. Importantly, B7-DC
does not inhibit the up-regulation of CD40L on CD4
 
 
 
 T
cells by B7–1 costimulation. Interestingly, at low concen-
trations of anti-CD3, B7-DC alone efficiently up-regulated
CD40L expression whereas B7–1 did not. The differential
kinetics and sensitivity of CD4 T cells to costimulation
with B7-DC versus B7–1 was not observed for other T cell
surface molecules such as CD25 and CD69 (data not de-
picted), which are involved in later stages of T cell activa-
tion than CD40L. These results suggest that B7-DC co-
stimulation is particularly important in modulating early
events in crosstalk between T cells and DC as CD40L in-
duced on T cells is a potent amplifier of DC function (18,
19) whereas B7-DC cross-linking has been shown to stim-
ulate CD40 expression by DCs (12).
In parallel to the above experiments, culture supernatants
were harvested at each time point of stimulation and tested
for cytokine secretion. B7–1 costimulated IL-2 secretion
much more efficiently than B7-DC (Fig. 2). Whereas B7–1
alone induced high production of IL-2 after 18 h stimula-
tion, significant IL-2 production was only observed after 48 h
with B7-DC alone. In contrast, both molecules demon-
strated a similar costimulation of IFN-
 
 
 
, which peaked af-
ter 48 h incubation. Strikingly, even though B7-DC dem-
onstrated a much weaker influence on IL-2 secretion than
B7–1, it synergized tremendously with B7–1 to costimulate
IL-2 production. Significant synergy was also observed in
the costimulation of IFN-
 
 
 
. Titration experiments (Fig. 2
c) demonstrated that B7-DC synergizes similarly with
B7–1 and B7–2.
At low anti-CD3 concentrations, which is thought to
mimic limiting signal 1 strength, significant levels of IL-2
and IFN-
 
 
 
 were detected only when T cells were costimu-
lated by a combination of B7–1/2 and B7-DC (Fig. 2).
These results suggest that the combined activity of B7-DC
and members of the B7–1/B7–2 system represent an im-
portant mechanism by which DCs uniquely initiate T cell
responses even at low antigen dose.
Because of the question of whether B7-DC costimula-
tion versus inhibition was dependent on the state of T cell
activation, we compared the function of B7-DC on un-
stimulated and preactivated CD4
 
 
 
 T cells using plate
bound anti-CD3. Fig. 2 d shows that, rather than inducing
inhibition of T cell functions, 2-d preactivation increased
the costimulatory effect of B7–1 and B7-DC, with B7–1
costimulation much more efficient than B7-DC. Of note,
the synergy between both molecules for costimulation of
IL-2 secretion still exists. However, even though the co-
stimulation of IFN-
 
 
 
 production by B7-DC or B7–1 is in-
creased, the synergistic effect is no longer observed with
preactivated T cells.
 
T Cell Costimulation Using B7–1, B7-DC, and B7–1/B7-
DC Transfectants.
 
As an alternative approach to individu-
ally reconstitute specific costimulatory signals, we trans-
fected RENCA cells with the B7–1 gene, B7-DC gene, or
both. RENCA, a BALB/c-derived tumor does not natu-
rally express B7–1, B7–2, B7-DC, or B7-H1 even after
IFN-
 
 
 
 treatment. IFN-
 
 
 
–treated RENCA and its various
transfectants express I-E
 
d
 
, allowing it to present HA
 
110–120
 
peptide to 6.5 transgenic CD4
 
 
 
 T cells. Fig. 3 shows that
the optimal stimulation of either unactivated 6.5 transgenic
CD4
 
 
 
 T cells required the presence of costimulatory mole-
cules. In all cases, the presentation of HA
 
110–120
 
 by RENCA
Figure 1. BMDCs from B7-DC /  mouse are deficient in stimulating
T cells. (a) BMDCs (104/well) from wt mice (diamond), B7-DC KO
mice (square), and B7–1/B7–2 double KO mouse (triangle) were cultured
with CD4  OT-II T cells (104/well) in the presence of the indicated con-
centrations of OVA323–339 peptide and proliferation was measured after 3 d.
(b) Supernatants from these cultures with BMDCs from wt mouse (open
bars), B7-DC KO mice (hatched bar), and B7–1/B7–2 double KO mice
(filled bars) were collected after 2 d and IL-2 and IFN-  were measured
by ELISA.T
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B7-DC Costimulates CD4
 
 
 
 T Cells Independent of PD-1
Figure 2. Immobilized B7-DC strongly costimulates CD4  T cells and
synergizes with B7–1. (a) FACS® analysis of CD40L expression. Purified
CD4  T cells were stimulated with 3 ng/well (left panel) or 30 ng/well
(right panel) of precoated anti-CD3 in presence or absence of an equimo-
lar amount of immobilized B7-DC-Ig and B7–1-Ig or the combination of
both. Cells were harvested at indicated times, washed, and stained 30 min
with PE-conjugated anti-CD40L mAb and FITC-conjugated anti-CD4
mAb. (b) Culture supernatants were collected at indicated times and as-
sayed for cytokine secretion by ELISA when T cells were stimulated with
3 ng/well (left) or 30 ng/well (right) of immobilized anti-CD3 alone, in
presence of plate bound B7-1-Ig, B7-DC-Ig, or both. Open bars, no
costimulation; gray bars, B7-1-Ig; hatched bars, B7-DC-Ig; black bars,
B7-1-Ig   B7-DC-Ig (c) B7-DC-Ig and B7-1-Ig titration. CD4  T cells
were stimulated with a constant amount of anti-CD3 (30 ng/well) in
presence of increasing quantities of immobilized B7-DC-Ig and/or in-
creasing amount of B7–1/2-Ig. Symbols: black squares, no B7–1/2-Ig;
black circles, 25 ng/ml B7–1-Ig; open circles, 50 ng/ml B7–1-Ig; black
triangles, 25 ng/ml B7–2-Ig; open triangles, 50 ng/ml B7–2-Ig. (d) Im-
mobilized B7-DC-Ig costimulates preactivated CD4  T cells as well as
resting T cells. Purified CD4  T cells freshly isolated from spleens or pre-
activated 2 d with plate-bound anti-CD3 (30 ng/well), were stimulated
with immobilized anti-CD3 (30 ng/well) in the presence or absence of
immobilized B7–1-Ig and/or B7-DC-Ig. Open bars, no costimulation;
gray bars, B7–1-Ig; hatched bars, B7-DC-Ig; black bars, B7–1-Ig   B7-DC-
Ig. Cytokine release was measured by ELISA on 24 h culture supernatants.T
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cells transfected with the combination of B7–1 and B7-DC
induced the greatest T cell proliferative responses. Simi-
larly, B7–2 
 
 
 
 B7-DC double transfectants induced signifi-
cantly greater proliferative responses among 6.5 CD4 T
cells than did B7–2 or B7-DC single transfectants (unpub-
lished data). To assess the potential of the transfectants
to stimulate truly naive T cells, we used T cells 6.5 trans-
genic mice with RAG KO background. In contrast
with RAG
 
 
 
/
 
 
 
 6.5 transgenic splenocytes, 6.5 transgenic
RAG
 
 
 
/
 
 
 
 T cells are extremely dependent on costimulatory
signals whereas they are much less costimulation dependent
when preactivated. Whereas naive 6.5 transgenic RAG
 
 
 
/
 
 
 
CD4
 
 
 
 T cells were activated neither by plain RENCA nor
B7–1 or B7-DC transfectants, they proliferated significantly
in response to HA peptide presented by B7–1/B7-DC
double transfectants.
 
B7-DC Costimulation of CD4
 
 
 
 T Cells Is PD-1 Indepen-
dent.
 
PD-1 was described as the receptor of B7-DC and
B7-H1 and has been shown to negatively modulate im-
mune responses (10, 13, 20). We therefore directly as-
sessed the participation of PD-1 in B7-DC costimulation
using CD4
 
 
 
 T cells from PD-1 KO mice. Fig. 4 shows
that immobilized B7-DC costimulates IL-2 and IFN-
 
 
 
 se-
cretion by B6 PD1
 
 
 
/
 
 
 
 as well as wt B6 T cells. Moreover,
the synergistic effect of B7-DC 
 
 
 
 B7–1 costimulation for
cytokine production was equivalent for T cells from PD-1
KO as for wt B6 mice. This finding demonstrates that
PD-1 is not necessary for the delivery of the positive co-
stimulatory signals by B7-DC. We found that B7-DC
similarly costimulates cytokine secretion by preactivated
PD-1
 
 
 
/
 
  CD4  T cells similarly to wt CD4  T cells. Fi-
nally, even in absence of PD-1 expression on preactivated
T cells, the synergy between B7 and B7-DC was observed
for IL-2 secretion but not for IFN-  production as ob-
served previously.
Synergistic effects between B7–1 and B7-DC on activa-
tion of the T cell clone AE-7, which expresses constitu-
tively high level of PD-1, were assessed using plate bound
anti-CD3 in presence of anti-CD28 or B7–1 and/or B7-
DC. Fig. 5 demonstrates that, even in the presence of
much higher levels of PD-1 than typically observed on ac-
tivated splenic or LN T cells directly out of the mouse, B7-
DC synergizes very efficiently for costimulation of IL-2
production. These results suggest that interaction of B7-
DC with the alternate receptor may override PD-1 medi-
ated effects.
Discussion
Multiple separate lines of evidence presented here sup-
port the notion that B7-DC, which is predominantly ex-
pressed on DCs, serves a significant costimulatory function
Figure 3. HA110–120 peptide presentation to specific HA-specific CD4  T cells by RENCA cells engineered to express B7-DC and/or B7–1 mole-
cules. CD4  T cells were purified from either fresh (left panels) or preactivated (right panels) splenocytes from TCR transgenic 6.5 mice (top panels) or
6.5 RAG KO mice (bottom panels). For the preactivated cells, splenocytes were cultured 4 d in vitro with 1  g/ml of HA 110–120 peptide. CD4  T cells
were then negatively selected and rested overnight. The indicated RENCA transfectants were treated 3 d with 10 ng/ml of IFN-  to induce expression
of I-Ed molecules and used to present HA peptide (10  g/ml) to the CD4  T cells. T cell proliferation with either 0 (filled bars) or 10  g/ml (open bars)
HA peptide was measured after 72 h by [3H]thymidine incorporation.T
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Figure 4. B7-DC costimulates PD1 /  CD4  T cells. (a) Purified CD4  T cells from wt (open bars) or PD-1 KO mice (filled bars) were stimulated
with 30 ng/well of precoated anti-CD3 in the presence or absence of immobilized B7-1-Ig, B7-DC-Ig, or B7–1-Ig   B7-DC-Ig. Culture supernatants
were collected at indicated times and assayed for cytokine secretion by ELISA.
Figure 5. B7-DC and anti-CD28 mAb
synergize for costimulation of IL-2 produc-
tion even in the presence of high levels of
PD-1. (a) AE-7 cells, which express high level
of PD-1 were cultured in presence of limiting
amounts of immobilized anti-CD3 with either
B7-DC-Ig, B7–1-Ig, anti-CD28 (at limiting
concentration), or indicated combinations. (b)
Culture supernatants were collected at 24 h
and assayed for IL-2 by ELISA.T
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for CD4  T cells. Prestimulated T cells demonstrate less
dependence on the synergistic action of B7-DC and B7–1,
though we never observed inhibition by B7-DC. Further-
more, B7-DC costimulation appears to be both coopera-
tive and synergistic with the B7–1/B7–2 system. This syn-
ergy is independent of PD-1, indicating that an alternative
B7-DC receptor mediates most, if not all of the B7-DC–
dependent costimulation of T cells.
Costimulation by B7-DC alone and in synergy with B7–1
was virtually identical in PD-1 /  versus wt T cells, dem-
onstrating the existence of a second B7-DC receptor that
transmits an activating signal to CD4  T cells. These results
are compatible with the findings of Wang et al. who found
that mutations in B7-DC that abrogate binding to PD-1 do
not inactivate its costimulatory activity (21).
The role of PD-1 in B7-DC physiology remains to be
definitively elucidated. Naive T cells engaging a DC would
not initially express much PD-1 but live LN imaging stud-
ies suggest that T cells remain attached to DCs for 48 h,
long enough for PD-1 expression to be induced (3). Our
studies with A.E7 cells, which express high levels of PD-1,
suggest that B7-DC can costimulate in the presence of am-
ple PD-1.
A number of lines of evidence support the idea that, de-
spite their structural similarity and genomic proximity, B7-
DC and B7-H1 have distinct immunologic activity. First,
while B7-DC is predominantly expressed on DCs and to a
lesser extent on some activated macrophages, B7-H1 is
more ubiquitously expressed on both hematopoetic and
nonhematopoetic tissues, including many tumors (9, 11,
22, 23). Second, B7-DC and B7-H1 bind to different sites
on PD-1 (21), which may mediate distinct signaling.
Latchman et al. reported that while B7-H1 inhibited B7–
1–mediated costimulation, B7-DC did not (10). Forced
expression of B7-H1 on tumors generally inhibits their im-
munologic rejection whereas forced B7-DC expression ap-
pears to activate antitumor immunity (unpublished data,
and Yang Liu, personal communication). Taken together,
these results suggest a model in which B7-DC plays a ma-
jor costimulatory role at the T cell priming phase (both as
DC activating receptor and costimulator) whereas B7-H1
plays a more complex role. Its expression on DCs likely
promotes priming of a subset of naive PD-1  T cells while
its expression in the periphery (and on tumors) downmod-
ulates effector responses by PD-1  T cells. Thus, these two
B7 family members likely play diverse and distinct rather
than redundant roles in immune regulation.
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